查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086840

全球mRNA癌症疫苗市場：市場機會、治療開發中的專有技術及臨床試驗洞察（2026年）

Global mRNA Cancer Vaccines Market Opportunity, Therapeutic Development Proprietary Technologies & Clinical Trials Insight 2026
出版日期: | 出版商: KuicK Research | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

全球mRNA癌症疫苗市場－市場機會、治療開發中的專有技術及臨床試驗洞察（2026）報告的主要發現與亮點：

  • 按地區和治療適應症分類的市場趨勢
  • 首款mRNA癌症疫苗預計2031年上市。
  • 臨床試驗中mRNA癌症疫苗的最新進展：超過70種疫苗
  • 目前最先進的臨床研發階段：III期
  • 主要mRNA癌症疫苗臨床開發進度的見解
  • 依公司、國家、適應症和臨床階段分析全球mRNA癌症疫苗臨床試驗。
  • 用於mRNA癌症疫苗開發的專有技術：超過10個平台
  • 競爭格局

mRNA癌症疫苗的必要性及本報告的意義

mRNA癌症疫苗領域取得了顯著進展，從實驗性技術發展成為成熟的新一代治療平台，主要得益於mRNA設計、脂質奈米顆粒遞送以及新抗原發現技術的創新。其核心在於編碼腫瘤特異性抗原，這些抗原可在患者體內合成，實現對癌組織的精準免疫攻擊。一些早期證據表明，mRNA癌症疫苗有望成為一種擴充性且精準的癌症治療工具。

然而，儘管該領域取得了進展，但大多數產品仍處於臨床前階段或尚未進入臨床試驗，這意味著這項技術仍處於商業化初期。雖然在免疫抗原性和療效方面已取得令人鼓舞的結果，但這些技術能否延長多種癌症患者的存活期仍需進一步驗證。因此，在個人化癌症治療法規結構的背景下，該領域可以被定義為創新與系統性臨床應用交會的領域。

本報告旨在為投資者和相關人員提供全球 mRNA 癌症疫苗市場的系統性觀點，包括當前臨床研究狀況、競爭格局、研發管線以及主要癌症適應症的商業性機會。

本報告所納入的臨床試驗分析

本報告系統分析了mRNA癌症疫苗研發的各個臨床研究階段，從早期人體試驗和臨床前開發到中期臨床試驗和旨在獲得監管部門批准的III期臨床試驗，並對已上市的疫苗進行了重新評估。臨床試驗涵蓋了從常見癌症到罕見癌症的廣泛腫瘤適應症，充分展現了mRNA技術在現代癌症免疫療法中日益重要的地位。

本分析也涵蓋了這些臨床計畫的關鍵特徵，包括單藥治療和聯合治療策略、目標適應症、治療方案、給藥途徑、研究設計方法、申辦機構以及藥物研發合作。此外，本分析基於安全性和有效性指標（例如緩解率、無惡化生存期和免疫反應持續時間）分析了所研究藥物的臨床結果。此外，本報告也探討了癌症mRNA疫苗與免疫查核點抑制劑和其他抗癌藥物合併應用的潛力，尤其是在黑色素瘤、肺癌、胃癌、乳癌和頭頸檢驗等固體癌的應用。

引領mRNA癌症疫苗研發的領導企業

全球mRNA癌症疫苗市場匯聚了許多創新製藥和生技公司。其中，擁有RNA技術平台和免疫腫瘤學專長的公司佔市場領先地位，尤其是BioNTech和Moderna Therapeutics，它們正在開發針對多種固體癌的個人化新抗原疫苗。

此外，CureVac、pHion Therapeutics 和 Immorna 等中型生物技術公司正在拓展其研發管線，這些管線基於多種技術，包括提高 RNA 分子穩定性、增強遞送機制以及採用新型抗原編碼方法。這些公司在個人化疫苗和即用型疫苗的研發中發揮積極作用，並利用自身平台探索投資和合作機會。

用於開發mRNA癌症疫苗的技術平台

平台化方法正逐漸成為mRNA癌症疫苗持續發展的核心要素，為企業提供了簡化潛在療法設計、最佳化和生產流程的機會。這些平台基於電腦輔助抗原設計、序列最佳化和遞送方法，能夠增強mRNA的穩定性、翻譯效率和免疫系統活化能力。模組化方法使開發人員能夠快速更改或組合靶點，縮短產品上市時間，降低風險，並確保疫苗開發在不同癌症類型中的一致性。

例如，Innovac Therapeutics 的全整合 mRNA 技術系統就是一個例子。該系統包含用於序列設計、密碼子和非翻譯區最佳化的計算工具，以及基於脂質奈米顆粒的遞送系統。該系統正被用於開發基於脂質奈米顆粒的 mRNA 癌症疫苗，這些疫苗旨在激活 CD4+ 和 CD8+ T 細胞反應。例如，癌症候選疫苗「INV002」就是利用該系統開發的。該系統包含用於序列設計的專有演算法工具和可防止 RNA 分解的 mRNA 遞送系統。

mRNA癌症疫苗的未來前景

mRNA癌症疫苗的未來前景包括將其應用範圍擴展到除黑色素瘤以外的其他高發腫瘤，例如非小細胞肺癌、大腸直腸癌、乳癌和消化器官系統癌症。隨著臨床數據的積累，這些疫苗將在治療過程的早期階段得到更廣泛的應用，尤其是在輔助性治療和微量殘存疾病（MRD）治療中，因為免疫啟動可以帶來更有效、更持久的治療反應。

推動這一成長的關鍵因素是基於生物標記的患者篩選，即透過新抗原識別和突變負荷評估進行篩選。這有望實現更精準的標靶治療並提高應答率。此外，人工智慧驅動的新抗原預測技術的整合有望提高疫苗設計的效率和臨床試驗的成功率。

從商業角度來看，mRNA癌症疫苗雖然仍處於早期階段，但它代表著一個快速發展的腫瘤治療平台，且風險較低。儘管商業化尚未開始，但成功的臨床研發管線、不斷擴展的聯合治療以及日益增強的監管參與表明，其發展路徑與以往免疫腫瘤學領域的突破性進展類似，呈現出多階段成長的特徵，預示著該領域將有進一步的拓展空間。

目錄

第1章：調查方法

第2章 mRNA疫苗作為下一代癌症免疫療法

  • mRNA疫苗概述
  • mRNA疫苗與其他癌症療法的比較
  • mRNA疫苗與其他疫苗的比較

第3章：全球mRNA癌症疫苗市場概覽

  • 當前市場趨勢
  • 未來市場機遇

第4章：癌症mRNA疫苗全球臨床試驗概述

  • 愛別
  • 公司
  • 國家
  • 適應症

第5章：全球mRNA癌症疫苗臨床試驗概覽（依公司、國家、適應症及分期分類）

  • 研究
  • 臨床前
  • 第一階段
  • 第一/二期
  • 第二階段
  • 第二/三期
  • 第三階段

第6章：mRNA癌症疫苗的全球臨床概述（按適應症分類）

  • 乳癌
  • 腦腫瘤
  • 黑色素瘤
  • 頭頸癌
  • 子宮頸癌
  • 肺癌
  • 胃腸道癌症

第7章：全球mRNA癌症疫苗市場趨勢（按國家/地區分類）

  • 美國
  • 俄羅斯
  • 中國
  • 澳洲
  • 歐洲
  • 加拿大
  • 英國

第8章：mRNA癌症疫苗研發的獨特技術與方法

第9章 競爭情勢

  • BioNTech
  • Combined Therapeutics
  • CureVac
  • EpiVax
  • HDT Bio
  • Immorna
  • Immune Design
  • MDimune
  • Moderna Therapeutics
  • NeoCura
  • pHion Therapeutics
  • Providence Therapeutics
  • RinuaGene
  • RNAimmune
  • TransCode Therapeutics

Global mRNA Cancer Vaccines Market Opportunity, Therapeutics Development Proprietary Technologies & Clinical Trials Insight 2026 Report Findings & Highlights:

  • Market Trends By Region & Therapeutic Indication
  • First mRNA Cancer Vaccine Commercial Availability Expected By 2031
  • Insight On mRNA Cancer Vaccines In Clinical Trials: > 70 Vaccines
  • Highest Clinical Phase Of Development: Phase-III
  • Key mRNA Cancer Vaccine Clinical Timeline Insights
  • Global mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication & Phase
  • Proprietary Technologies For mRNA Cancer Vaccine Development: >10 Platforms
  • Competitive Landscape

Need For mRNA Cancer Vaccines & Why This Report

The landscape of mRNA cancer vaccines has seen considerable advancement from experimental technology to a well proven next generation therapy platform, fueled by innovations in mRNA design, delivery through lipid nanoparticles and neoantigen discovery methods. The core principle is based on the coding of tumor specific antigens, which are synthesized inside patients' bodies, thus making a precise immune attack on the cancer tissue possible. There is some early evidence suggesting that mRNA cancer vaccines can become scalable and precise cancer treatment tools.

However, despite the advancements in this area, the technology still finds itself in the early commercialization phase, as majority of the products are yet to enter clinical trials or are in their preclinical stages. Despite positive results concerning immunogenicity and efficacy, their ability to prolong life in many kinds of cancer still needs to be established. Thus, this area can be defined as one that stands at the intersection of innovation and structured clinical application with the help of developing personalized cancer treatments regulatory frameworks.

The purpose of this report is to give investors and stakeholders a structure oriented view of the global mRNA cancer vaccine market, providing an overview of the existing state of the clinical research in the industry, competition, pipeline and commercial opportunities in the major oncological indications.

Clinical Trials Insight Included in Report

This report includes the structured analysis of mRNA cancer vaccine development across all stages of clinical research, starting from early human studies and preclinical developments up to mid-phase trials and registration oriented Phase III trials, as well as reevaluation of already established vaccines. The scope of clinical trials includes a broad spectrum of oncology indications encompassing high incidence and rare cancers, indicating the increasing relevance of mRNA technology to contemporary cancer immunotherapy.

The analysis also covers important features of these clinical programs, including monotherapy versus combination treatment strategies, indication focus, lines of therapy, administration route, trial design approach, sponsor organization, and collaboration in drug development. Moreover, the clinical performance of the reviewed drugs in terms of safety and efficacy metrics such as response rate, progression free survival, and duration of immune response will be analyzed. Furthermore, the report will examine the potential of mRNA vaccines for cancer in combination with immune checkpoint inhibitors and other anti-cancer agents, especially in the case of solid tumors, including melanoma, lung, gastric, breast, and head and neck cancers.

Major Companies Driving mRNA Cancer Vaccine R&D

In the global mRNA cancer vaccines market, there are several innovative pharmaceutical companies and biotech companies operating. The leading positions in the market belong to the companies that have RNA technology platforms and immune oncology know how, notably BioNTech and Moderna Therapeutics that are developing personalized neoantigen vaccines for several solid tumors.

Additionally, medium-sized biotechnology players like CureVac, pHion Therapeutics, and Immorna are scaling their pipelines based on approaches that include improved stability of RNA molecules, enhanced delivery mechanisms, and novel approaches to the coding of antigens. These companies are playing an active role in developing personalized and off the shelf vaccines, and are leveraging their platforms in seeking investment and collaboration opportunities.

Technology Platforms Used For mRNA Cancer Vaccines Development

Platform approaches are emerging as core elements of the ongoing evolution of mRNA vaccines for cancer, offering companies opportunities to streamline the design, optimization, and manufacturing of potential therapeutics. These platforms are based on computational antigen design, sequence optimization, and delivery methods for enhancing mRNA stability, translation, and activation of the immune system. Using modular approaches, developers are able to swiftly change or combine targets, minimize time to market, reduce risks, and maintain consistency in the development of vaccines for various types of cancer.

An example of this could be Innovac Therapeutics' fully integrated mRNA technology system that consists of computational tools for sequence design, codon and untranslated regions optimization, and lipid nanoparticle-based delivery systems. This system is employed in development of lipid nanoparticle-based mRNA cancer vaccines targeting activation of both CD4+ and CD8+ T-cell response. For instance, an example would be candidate cancer vaccine INV002 that is being developed through application of this system involving proprietary algorithmic tools for sequence design and mRNA delivery system capable of protecting the RNA from degradation.

Future Outlook For mRNA Cancer Vaccines

Future opportunities for mRNA cancer vaccines include expansion to higher incidence tumors other than melanoma, including non-small cell lung cancer, colorectal cancer, breast cancer, and gastrointestinal cancers. With the maturation of clinical data, these vaccines will increasingly be used at early stages of the pathway, especially at adjuvant and minimal residual disease settings where immune priming can result in more effective and durable responses.

An important factor behind the growth is anticipated to be biomarker-based patient selection through neoantigen identification and mutation burden assessment, providing more accurate targets and improving response rates. Integration of AI based neoantigen prediction will also boost the efficiency of vaccine design and the chances of success in clinical trials.

From the business point of view, mRNA cancer vaccines appear to be an early, but rapidly de-risked oncology platform. Although commercialization has not started yet, successful clinical pipelines, broadening combination therapies, and growing regulatory involvement indicate the presence of a multi-stage growth path akin to earlier immuno-oncology breakthroughs, implying further expansion of the field.

Table of Contents

1. Research Methodology

2. mRNA Vaccines As Next Generation Cancer Immunotherapy

  • 2.1 mRNA Vaccines Overview
  • 2.2 mRNA Vaccines v/s Other Cancer Therapeutic Approaches
  • 2.3 mRNA Vaccines v/s Other Vaccines

3. Global mRNA Cancer Vaccines Market Overview

  • 3.1 Current Market Trends
  • 3.2 Future Market Opportunities

4. Global Cancer mRNA Vaccines Clinical Trails Overview

  • 4.1 By Phase
  • 4.2 By Company
  • 4.3 By Country
  • 4.4 By Indication

5. Global mRNA Cancer Vaccine Clinical Trials Insight By Company, Country, Indication & Phase

  • 5.1 Research
  • 5.2 Preclinical
  • 5.3 Phase I
  • 5.4 Phase I/II
  • 5.5 Phase II
  • 5.6 Phase II/III
  • 5.7 Phase III

6. Global mRNA Cancer Vaccines Clinical Landscape By Indication

  • 6.1 Breast Cancer
  • 6.2 Brain Cancers
  • 6.3 Melanoma
  • 6.4 Head & Neck Cancers
  • 6.5 Cervical Cancer
  • 6.6 Lung Cancer
  • 6.7 Gastrointestinal Cancers

7. Global mRNA Cancer Vaccines Market Trends By Country

  • 7.1 US
  • 7.2 Russia
  • 7.3 China
  • 7.4 Australia
  • 7.5 Europe
  • 7.6 Canada
  • 7.7 UK

8. Proprietary Technologies & Methodologies For mRNA Cancer Vaccine Development

9. Competitive Landscape

  • 9.1 BioNTech
  • 9.2 Combined Therapeutics
  • 9.3 CureVac
  • 9.4 EpiVax
  • 9.5 HDT Bio
  • 9.6 Immorna
  • 9.7 Immune Design
  • 9.8 MDimune
  • 9.9 Moderna Therapeutics
  • 9.10 NeoCura
  • 9.11 pHion Therapeutics
  • 9.12 Providence Therapeutics
  • 9.13 RinuaGene
  • 9.14 RNAimmune
  • 9.15 TransCode Therapeutics

List of Figures

  • Figure 3-1: Global mRNA Cancer Vaccines Market - Future Market Opportunities
  • Figure 4-1: Global - Number Of mRNA Cancer Vaccines In Clinical Trials By Phase, 2026
  • Figure 4-2: Global - Number Of mRNA Cancer Vaccines In Clinical Trials By Company, 2026
  • Figure 4-3: Global - Number Of mRNA Cancer Vaccines In Clinical Trials By Country, 2026
  • Figure 4-4: Global - Number Of mRNA Cancer Vaccines In Clinical Trials By Indication, 2026
  • Figure 6-1: KEYNOTE-942 Phase II (NCT03897881) Study - Initiation & Completion Year
  • Figure 6-2: INTerpath-001 Phase III (NCT05933577) Study - Initiation & Completion Year
  • Figure 6-3: AHEAD-MERIT Phase II (NCT04534205) Study - Initiation & Completion Year
  • Figure 6-4: KEYNOTE-603 Phase I (NCT03313778) Study - Initiation & Completion Year
  • Figure 6-5: EVM14C101 Phase I/II (NCT07095868) Study - Initiation & Completion Year
  • Figure 6-6: RG002-A1201 Phase I/II (NCT06273553) Study - Initiation & Completion Year
  • Figure 6-7: INTerpath-002 Phase III (NCT06077760) Study - Initiation & Completion Year
  • Figure 6-8: LuCa-MERIT-1 Phase I (NCT05142189) Study - Initiation & Completion Year
  • Figure 6-9: EMPOWERVAX Lung 1 Phase II (NCT05142189) Study - Initiation & Completion Year
  • Figure 6-10: 19-039 Phase I (NCT04161755) Study - Initiation & Completion Year
  • Figure 6-11: IMCODE003 Phase II (NCT05968326) Study - Initiation & Completion Year
  • Figure 6-12: BNT122-01 Phase II (NCT04486378) Study - Initiation & Completion Year
  • Figure 8-1: BioNTech - uRNA Products
  • Figure 8-2: BioNTech - iNeST Technology
  • Figure 8-3: CureVac - Proprietary Method For Generation Of mRNA Therapeutics
  • Figure 8-4: Moderna - mRNA Technology
  • Figure 8-5: NeoCura - NeoCura Ag Platform
  • Figure 8-6: Providence Therapeutic - mRNA Medicines Platform Benefits
  • Figure 8-7: RinuaGene - Targeted Delivery
  • Figure 8-8: RinuaGene - RNA Engineering
  • Figure 8-9: RinuaGene - Robust CMC
  • Figure 8-10: RinuaGene - Data Science & AI
  • Figure 8-11: MOPCTx Platform - Molecular Adjuvantation Cancer Vaccine Workflow

List of Tables

  • Table 2-1: mRNA Vaccines v/s Other Cancer Therapeutic Approaches
  • Table 2-2: mRNA-Based Cancer Vaccines v/s Other Cancer Vaccines
  • Table 3-1: Regulatory Designations Granted To Investigational mRNA Cancer Vaccines